| Document |
Document Title |
|
WO/2023/240156A9 |
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
|
|
WO/2024/070946A1 |
The present invention provides a composition for semiconductor devices which has the excellent ability to remove dry-etching residues and is more inhibited from causing the dissolution of tungsten and which, when works are treated therew...
|
|
WO/2024/059090A1 |
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...
|
|
WO/2024/059017A2 |
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...
|
|
WO/2024/042952A1 |
The present invention provides: an acid generator which exhibits excellent solubility in a cationically curable compound; and a curable composition which is rapidly cured when subjected to a heat treatment, and which forms a cured produc...
|
|
WO/2024/040358A1 |
The present disclosure is generally directed to the extraction of active compounds from plant biomass. In particular, the present disclosure is directed to the extraction of active compounds from plant biomass using solvents of different...
|
|
WO/2024/042951A1 |
Provided is an acid generator that has superior solubility in cation-curable compounds. This acid generator includes: a salt (1) of a cation represented by formula (c-1) and a monovalent counter anion; and a salt (2) of a cation repres...
|
|
WO/2024/022263A1 |
A lipid compound and a lipid nanoparticle composition. The lipid compound has a structure represented by formula (I), and can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-conjugated...
|
|
WO/2024/006226A1 |
Provided are N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, for example, as receptor probes, as modulators of neurotransmission, and as therapeutic agents, for example as CNS agents. Als...
|
|
WO/2023/241140A1 |
The present invention relates to the technical field of biological medicine, particularly to use of a class of substituted diaryl compounds in the preparation of anti-inflammatory drugs. The compounds have a structure represented by form...
|
|
WO/2023/244200A1 |
The invention is a method of obtaining R-propranolol HC1 in enantiomeric purity by microbial stereoinversion method using Rhizopus oryzae CBS 111718 microorganism as the enzyme source from the racemic mixture of propranolol HC1, which is...
|
|
WO/2023/240156A1 |
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
|
|
WO/2023/230649A1 |
The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/227029A1 |
The present invention relates to a novel crystal form of elacestrant (hereinafter referred to as "compound I") dihydrochloride, a preparation method therefor, a pharmaceutical composition containing the crystal form, and uses of the crys...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/209033A1 |
In one aspect, the present invention relates to a method for crystallizing (2R,3R)-3-(3- methoxyphenyl)-N,N,2-trimethylpentan-1-amine or salts thereof (compound I), the method comprising the following steps: (i) mixing compound I with a ...
|
|
WO/2023/202554A1 |
Disclosed are a chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I), and the definition of each group is given in the description...
|
|
WO/2023/200015A1 |
The present invention provides: iron phosphide nanoparticles which are stable in the atmosphere, and in which iron atoms are in a low valence state; a method for producing the iron phosphide nanoparticles; and a reduction catalyst. The p...
|
|
WO/2023/194382A1 |
Disclosed herein is a salt of formula (I): wherein q is + or –; p is 2+, +, – or 2–; g is 1 or 2; G is selected from R5-C≡C-CO2 –, R5- C≡C-C(=O)S–, R5-C≡C-CS2 –, R5-C≡C-SO2 –, R5-C≡C-S(=O)S–, R5-C≡C-SO3 –, R...
|
|
WO/2023/176209A1 |
A tosylic acid anionic ionic liquid represented by formula (1) is a unique compound that is especially stable in supercooled conditions and maintains a liquid state especially easily, even among ionic liquids, and can be handled as a liq...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/171694A1 |
Provided in an embodiment is a core-shell type heterogeneous catalyst provided with a core 1 and a shell 2 positioned on the outside of the core 1, wherein the shell 2 contains a metal complex structure 3 containing a Josiphos ligand.
|
|
WO/2023/156450A1 |
There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, m...
|
|
WO/2023/156453A1 |
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and k...
|
|
WO/2023/153504A1 |
A nucleic acid delivery material containing a perylene-diimide-ring-free polycyclic aromatic compound having one or more primary, secondary, or tertiary amino groups or nitrogen-cation-containing groups has exceptional efficiency in nucl...
|
|
WO/2023/019244A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/149559A1 |
[Problem] The present invention provides a catalyst for hydrogenation reactions, the catalyst having excellent catalyst durability and being capable of selectively hydrogenating only some functional groups and/or unsaturated bonds of an ...
|
|
WO/2023/143600A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...
|
|
WO/2023/141469A2 |
Provided are compounds of Formulae (I), (II) and (III) and therapeutic use of the compounds:
|
|
WO/2023/134145A1 |
The present invention provides a preparation method for a tivozanib key intermediate compound of formula I, 2-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)-aniline. Compound of formula VI, 4-chloro-6,7-dimethoxyquinoline and compound of for...
|
|
WO/2023/137044A2 |
Described herein are methods of making (Z)-endoxifen, a salt thereof, crystalline forms of endoxifen, and compositions comprising them. Also described herein are crystalline forms of (Z)-endoxifen. A method of making (Z)-endoxifen may in...
|
|
WO/2023/135035A1 |
A process for the manufacture of alkanolamines and/or a process for the conversion of al-kanolamines wherein the process is performed in one or equipment items, wherein one or more steel parts of the one or more equipment items, which ha...
|
|
WO/2023/125738A1 |
Provided are a lipid and a composition used for delivery. Specifically provided is a compound represented by formula I or a salt thereof, wherein R1 to R3, H1 to H3, L1, and L2 are as defined in the description.
|
|
WO/2023/117111A1 |
The invention relates to an especially recyclable composite material which consists of at least two material layers (1, 4) bonded by a layer (2) of adhesive. For an easy and clean separation of the two material layers the adhesive consis...
|
|
WO/2023/115220A1 |
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexac...
|
|
WO/2023/121753A1 |
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...
|
|
WO/2023/117112A1 |
The invention relates to a compound material, especially a recyclable composite material which consists of at least two material layers (1, 2) bonded by a layer (2) of adhesive. For an easy and clean separation of the two material layers...
|
|
WO/2023/122276A1 |
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor positive allosteric modulators (PAMS), compositions comprising the compounds, and methods of using the compounds and compositions comprising the c...
|
|
WO/2023/118833A1 |
1. In one aspect, a process for the preparation of vilanterol ((R)-4-(2-((6-(2-((2,6- dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hy
droxymethyl)phenol; Compound VI) or a pharmaceutically acceptable salt thereof, comprises ...
|
|
WO/2023/103611A1 |
The present invention belongs to the field of the synthesis of fine chemical intermediates, and discloses a bromopyrene intermediate and derivatives thereof, a preparation method, and use. The bromopyrene intermediate has a molecular str...
|
|
WO/2023/098203A1 |
Disclosed in the present invention is a production method for 4,4'-diaminodiphenyl ether, which relates to the technical field of the hydrogenation synthesis of aromatic nitro compounds. According to the production method for 4,4'-diamin...
|
|
WO/2023/102381A1 |
Methods and compositions for treating RNA viral infections, including behavior symptoms of the RNA viral infections, are disclosed herein. Also disclosed are methods and compositions for reducing the progression of clinical complications...
|
|
WO/2023/098622A1 |
Disclosed are a small molecule binding ligand of a α-synuclein aggregate, and a preparation method therefor and a use thereof. The small molecule binding ligand of a α-synuclein aggregate is a compound shown in the following general fo...
|
|
WO/2023/098592A1 |
The present invention provides a carbon-loaded iron-based catalyst, and a preparation method thereof and a use. The preparation method comprises dissolving ferric chloride in water, adding activated carbon, adding sodium hydroxide at 60-...
|
|
WO/2023/085256A1 |
The present invention provides a fluorine-containing ether compound which is represented by the following formula. R1-O-R2-CH2-R3-CH2-R4-CH2-R5-CH2-R6-CH2 -R7-CH2-R8-O-R9 (In the formula, R3, R5 and R7 represent same perfluoropolyether c...
|
|
WO/2023/087034A1 |
Disclosed herein are salts and solid forms of 4-bromo-2,5-dimethoxyphenethylamine. The solid form may be a salt and/or a crystalline form of 4-bromo-2,5-dimethoxyphenethylamine, such as a polymorph of 4-bromo-2,5-dimethoxyphenethylamine ...
|
|
WO/2023/072434A1 |
The invention relates to new spermine derivatives of Formula (I), wherein the meaning of the groups R1, R2, n and m is defined in the description, to a pharmaceutical composition thereof and to their use as heparin antidotes in the contr...
|
|
WO/2023/074527A1 |
The present invention addresses the problem of providing: a crystalline composition comprising a benzoxazine compound represented by general formula (1); and a method for producing same. As a solution, provided is a crystalline compositi...
|
|
WO/2023/067624A1 |
The present invention provides a method for the preparation of building blocks of 2,7-dihydroxy-9-fluorenone towards the synthesis of tilorone dihydrochloride salt and other salts (bromide, iodide, fluoride, citrate, oxalate, maleate, ph...
|
|
WO/2023/061460A1 |
Provided is a novel cationic lipid having a structure as represented in general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pha...
|
